THERAPEUTICSMD INC (TXMD)

TherapeuticsMD Announces Full Year 2023 Financial Results

TherapeuticsMD exploring strategic alternatives for company (NASDAQ:TXMD)

TherapeuticsMD (TXMD) said it is exploring strategic alternatives for the company, including a possible business combination or asset sale. Read more here.

TherapeuticsMD Announces Third Quarter 2023 Financial Results

TherapeuticsMD Announces Second Quarter 2023 Financial Results

TherapeuticsMD Announces First Quarter 2023 Financial Results

TherapeuticsMD Announces Full Year 2022 Financial Results and Provides Update on Business Model Transition

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

We're starting off the week with a breakdown of the biggest pre-market stock movers traders will want to watch for Monday!

TherapeuticsMD Completes Transaction to License Its Products to Mayne Pharma

TherapeuticsMD Announces Definitive Agreements to License its Products to Mayne Pharma

TherapeuticsMD Announces Third Quarter 2022 Financial Results

TherapeuticsMD Announces Additional $7 Million Private Placement

TherapeuticsMD Announces $7 Million Private Placement

TherapeuticsMD Appoints Dr. Brian Bernick and Mr. Mark Glickman as Interim Co-Chief Executive Officers

TherapeuticsMD Announces Second Quarter 2022 Financial Results

TherapeuticsMD to Report Second Quarter 2022 Financial Results on August 15, 2022